CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1

Shubhnita Singh, Ariane Bruder-Nascimento, Eric J. Belin de Chantemele, Thiago Bruder-Nascimento

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: Chemokine (C- Cmotif) ligand 5 (CCL5) and its receptor C-C motif chemokine receptor 5 (CCR5), have been broadly studied in conjunction with infectious pathogens, however, their involvement in cardiovascular disease is not completely understood. NADPH oxidases (Noxs) are the major source of reactive oxygen species (ROS) in the vasculature. Whether the activation of Noxs is CCL5/CCR5 sensitive and whether such interaction initiates vascular injury is unknown. We investigated whether CCL5/CCR5 leads to vascular damage by activating Noxs. Material and methods: We used rat aortic smooth muscle cells (RASMC) to investigate the molecular mechanisms by which CCL5 leads to vascular damage and carotid ligation (CL) to analyze the effects of blocking CCR5 on vascular injury. Results: CCL5 induced Nox1 expression in concentration and time-dependent manners, with no changes in Nox2 or Nox4. Maraviroc pre-treatment (CCR5 antagonist, 40uM) blunted CCL5-induced Nox1 expression. Furthermore, CCL5 incubation led to ROS production and activation of Erk1/2 and NFkB, followed by increased vascular cell migration, proliferation, and inflammatory markers. Notably, Nox1 inhibition (GKT771, 10uM) blocked CCL5-dependent effects. In vivo, CL induced pathological vascular remodeling and inflammatory genes and increased Nox1 and CCR5 expression. Maraviroc treatment (25 mg/Kg/day) reduced pathological vascular growth and Nox1 expression. Conclusions: Our findings suggest that CCL5 activates Nox1 in the vasculature, leading to vascular injury likely via NFkB and Erk1/2. Herein, we place CCR5 antagonists and/or Nox1 inhibitors might be preeminent antiproliferative compounds to reduce the cardiovascular risk associated with medical procedures (e.g. angioplasty) and vascular diseases associated with vascular hyperproliferation.

Original languageEnglish (US)
Article number114859
Pages (from-to)114859
JournalBiochemical Pharmacology
StatePublished - Jan 2022


  • Animals
  • CCR5 Receptor Antagonists/pharmacology
  • Cell Movement/drug effects
  • Cells, Cultured
  • Chemokine CCL5/genetics
  • Gene Expression Regulation/drug effects
  • Male
  • Maraviroc/pharmacology
  • Mice, Inbred C57BL
  • Muscle, Smooth, Vascular/cytology
  • Myocytes, Smooth Muscle/drug effects
  • NADPH Oxidase 1/genetics
  • Rats
  • Receptors, CCR5/agonists
  • Recombinant Proteins/pharmacology
  • Vascular System Injuries/metabolism


Dive into the research topics of 'CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1'. Together they form a unique fingerprint.

Cite this